Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epidermal growth factor cancer vaccine - Bioven

Drug Profile

Epidermal growth factor cancer vaccine - Bioven

Alternative Names: BV NSCLC 001; BV NSCLC 002; BVN-NSCLC-002; Center of Molecular Immunology (CIMA) Epidermal Growth Factor (EGF) Vaccine; Center of Molecular Immunology Epidermal Growth Factor Vaccine; CimaVax EGF; CIMAvax Epidermal Growth Factor Vaccine; CIMAvax IM; CIMAvax-EGF; EGF cancer vaccine; EGF-P64K cancer vaccine; EGF-PTI; hrEGF-rP64k-Montanide ISA 51 VG; Recombinant human EGF-P64K/montanide Vaccine; Recombinant human EGF-rP64K/montanide ISA 51 vaccine; rEGF-P64K/Montanide ISA 51 vaccine; SAI-EGF

Latest Information Update: 16 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Center of Molecular Immunology
  • Developer Bioven; Center of Molecular Immunology; National Cancer Institute (USA); Roswell Park Cancer Institute
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase II Prostate cancer
  • Discontinued Colorectal cancer; Gastric cancer

Most Recent Events

  • 06 Sep 2019 Bioven terminates a phase III trial in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease) in Bulgaria, Georgia, Poland, Romania, Spain, Malaysia, Philippines, Thailand, Czech Republic, Germany and the UK due to sponsor decision based on slow recruitment and new emerging drug combinations (NCT02187367) (EudraCT2013-005335-25)
  • 15 Jan 2019 Center of Molecular Immunology plans a phase II/III trial for Prostate Cancer (Castration resistant) in Cuba (RPCEC00000291)
  • 01 Oct 2018 Roswell Park Comprehensive Cancer Center and Center of Molecular Immunology launch a joint venture, Innovative Immunotherapy Alliance, between USA and Cuban partners
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top